Recent Updates
Recently added Catalysts
COLL

Collegium to Participate in H.C. Wainwright Global Investment Conference

Key Takeaway: STOUGHTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will present at the H.C. Wainwright Global Investment Conference being held at the Fontainebl
Price reaction · baseline $15.51 (2022-05-16 close) · hit after-hours · clean, no other COLL news in the window
day 0 close · peak
+1.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
0.4%
average across 3 past catalysts
Lead asset
DFN-15 Active
Phase 3 · Migraine Headache

Full Press Release Details

STOUGHTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will present at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.
Details of the event are as follows:
Presentation Date and Time: Tuesday, May 24, 2022, at 3:30 pm ET
About Collegium Pharmaceutical, Inc.
Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Last updated: May 17, 2022